Andrew Dreyfus - 10 Jun 2025 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
10 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 16:26:22 UTC
Previous filing
15 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dreyfus Andrew Director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON /s/ Brian Tessler, Attorney-in-Fact 12 Jun 2025 0001670893

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Award $0 +45,000 +25% $0.000000 228,313 10 Jun 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
F2 Since the date of the reporting person's last ownership report, the individual transferred 4,917 shares of Class A common stock to the individual's ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the individual's ex-spouse.

Remarks:

Exhibit 24 - Power of Attorney